T1 signal intensity in the dentate nucleus after the administration of the macrocyclic gadolinium-based contrast agent gadoterate meglumine: An observational study.

Autor: Ramalho J; Departamento de Neurorradiología, Centro Hospitalar Lisboa Central, Lisboa, Portugal. Electronic address: jmpmramalho@gmail.com., Semelka RC; Dr. Richard Semelka. Empresa Privada de Consultoría., Cruz J; Departamento de Radiología, Hospital Garcia de Orta, EPE, Almada, Portugal; Departamento de Radiología, Hospital da Luz, Lisboa y Setúbal, Portugal., Morais T; Departamento de Neurorradiología, Centro Hospitalar Lisboa Central, Lisboa, Portugal., Ramalho M; Departamento de Radiología, Hospital Garcia de Orta, EPE, Almada, Portugal; Departamento de Radiología, Hospital da Luz, Lisboa y Setúbal, Portugal. Electronic address: miguel-ramalho@netcabo.pt.
Jazyk: angličtina
Zdroj: Radiologia [Radiologia (Engl Ed)] 2022 Sep-Oct; Vol. 64 (5), pp. 397-406. Date of Electronic Publication: 2022 Jun 02.
DOI: 10.1016/j.rxeng.2020.07.006
Abstrakt: Introduction and Aims: Contradictory results have been reported about hyperintensity of the globus pallidus and/or dentate nucleus on unenhanced T1-weighted magnetic resonance (MR) images after exposure to various gadolinium-based contrast agents. This change in signal intensity varies with different gadolinium-based contrast agents. We aimed to determine whether signal intensity in the dentate nucleus is increased in unenhanced T1-weighted images in patients who have undergone multiple studies with the macrocyclic gadolinium-based contrast agent gadoterate meglumine. We thoroughly reviewed the literature to corroborate our results.
Materials and Methods: We included patients who had undergone more than 10 MR studies with gadoterate meglumine. We quantitatively analyzed the signal intensity in unenhanced T1-weighted MR images measured in regions of interest placed in the dentate nucleus and the pons, and we calculated the dentate nucleus-to-pons signal intensity ratios and the differences between the ratio in the first MR study and the last MR study. We used t-tests to evaluate whether the differences between the signal intensity ratios were different from 0. We also analyzed the subgroups of patients who had been administered <15 and ≥15 doses of gadoterate meglumine. We used Pearson correlation to determine the relationships between the differences in the signal intensity ratios and the number of doses of gadoterate meglumine administered.
Results: The 54 patients (26 men) had received a mean of 13.8±3.47 doses (range, 10-23 doses). The difference in the dentate nucleus-pons signal intensity ratio between the first and last MR study was -0.0275±0.1917 (not significantly different from 0; p=0.2968) in the entire group, -0.0357±0.2204 (not significantly different from 0; p = 0.351 in the patients who had received <15 doses (n=34), and -0.0135±0.1332 (not significantly different from 0; p = 0.655) in those who had received ≥15 doses (n=20). Differences in signal intensity ratios did not correlate significantly with the accumulated dose of gadoterate meglumine (P = 0.9064; ρ = -0.0164 [95%]).
Conclusions: Receiving more than 10 doses of gadoterate meglumine was not associated with increased signal intensity in the dentate nucleus.
(Copyright © 2020 SERAM. Published by Elsevier España, S.L.U. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: